Abstract 463P
Background
Delirium represents global brain dysfunction caused by an underlying medical condition. In cancer, it is associated with worse outcome. Antipsychotic medications have been widely used, however evidence in cancer populations is still limited with concern of potential adverse effects.
Methods
A comprehensive search was conducted among PubMed, EMBASE, Science Direct, and Scopus. Keywords used in this systematic review were antipsychotic agents, delirium, and neoplasm. Publications were limited to English manuscripts published in the last 15 years. Quality of each studies were assessed with Newcastle-Ottawa Scale (NOS).
Results
This review included 11 studies with a total of 1,896 patients aged 23 to 99. The cancer types varied and included lungs, gastrointestinal, hepatobiliary, urological, breast, head and neck, pancreas, lymphoma, sarcoma, and skin cancers. Some studies involved patients with brain metastasis and central nervous system lesions. These studies covered different cancer stages, including advanced, terminal, and localized. The antipsychotic medications examined in this review were haloperidol, quetiapine, chlorpromazine/levomepromazine, olanzapine, risperidone, trazodone, aripiprazole, and perospirone. Both typical and atypical antipsychotics were found to be similarly effective in managing delirium, but typical antipsychotics were associated with a higher prevalence of extrapyramidal symptoms. Higher antipsychotic doses were linked to increased mortality in cancer patients with delirium. Delirium outcomes were assessed using scales such as the Memorial Delirium Assessment Scale (MDAS), Richmond Agitation-Sedation Scale Palliative version (RASS-PAL), and others. Adverse events included hypotension, hypokinesia, sedation, extrapyramidal symptoms, falls, aspiration pneumonia, and urinary retention. Notably, no deaths were reported as a result of antipsychotic therapy.
Conclusions
Antipsychotic interventions to manage delirium in cancer patients consistently showed positive effects in addressing immediate distress and become a meaningful component of end-of-life support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract